Skip to main content

Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.

Publication ,  Journal Article
DiNardo, CD; Stein, EM; Pigneux, A; Altman, JK; Collins, R; Erba, HP; Watts, JM; Uy, GL; Winkler, T; Wang, H; Choe, S; Liu, H; Wu, B ...
Published in: Leukemia
November 2021

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Leukemia

DOI

EISSN

1476-5551

Publication Date

November 2021

Volume

35

Issue

11

Start / End Page

3278 / 3281

Location

England

Related Subject Headings

  • Survival Rate
  • Pyridines
  • Prognosis
  • Neoplasm Recurrence, Local
  • Mutation
  • Middle Aged
  • Male
  • Leukemia, Myeloid, Acute
  • Isocitrate Dehydrogenase
  • Immunology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
DiNardo, C. D., Stein, E. M., Pigneux, A., Altman, J. K., Collins, R., Erba, H. P., … de Botton, S. (2021). Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. Leukemia, 35(11), 3278–3281. https://doi.org/10.1038/s41375-021-01229-x
DiNardo, Courtney D., Eytan M. Stein, Arnaud Pigneux, Jessica K. Altman, Robert Collins, Harry P. Erba, Justin M. Watts, et al. “Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.Leukemia 35, no. 11 (November 2021): 3278–81. https://doi.org/10.1038/s41375-021-01229-x.
DiNardo CD, Stein EM, Pigneux A, Altman JK, Collins R, Erba HP, et al. Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. Leukemia. 2021 Nov;35(11):3278–81.
DiNardo, Courtney D., et al. “Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant.Leukemia, vol. 35, no. 11, Nov. 2021, pp. 3278–81. Pubmed, doi:10.1038/s41375-021-01229-x.
DiNardo CD, Stein EM, Pigneux A, Altman JK, Collins R, Erba HP, Watts JM, Uy GL, Winkler T, Wang H, Choe S, Liu H, Wu B, Kapsalis SM, Roboz GJ, de Botton S. Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant. Leukemia. 2021 Nov;35(11):3278–3281.

Published In

Leukemia

DOI

EISSN

1476-5551

Publication Date

November 2021

Volume

35

Issue

11

Start / End Page

3278 / 3281

Location

England

Related Subject Headings

  • Survival Rate
  • Pyridines
  • Prognosis
  • Neoplasm Recurrence, Local
  • Mutation
  • Middle Aged
  • Male
  • Leukemia, Myeloid, Acute
  • Isocitrate Dehydrogenase
  • Immunology